When was Sonoma Biotherapeutics founded?
Sonoma Biotherapeutics was founded in 2020.
Where is Sonoma Biotherapeutics's headquarters?
Sonoma Biotherapeutics's headquarters is located at 400 E. Jamie Ct, San Francisco.
What is Sonoma Biotherapeutics's latest funding round?
Sonoma Biotherapeutics's latest funding round is Series B.
How much did Sonoma Biotherapeutics raise?
Sonoma Biotherapeutics raised a total of $335M.
Who are the investors of Sonoma Biotherapeutics?
Investors of Sonoma Biotherapeutics include 8VC, ARCH Venture Partners, JDRF T1D Fund, Lilly Asia Ventures, Alexandria Venture Investments and 22 more.
Who are Sonoma Biotherapeutics's competitors?
Competitors of Sonoma Biotherapeutics include Quell Therapeutics.
You May Also Like
TxCell is dedicated to the development of therapeutic products for severe chronic inflammatory and autoimmune diseases with hight unmet medical need including inflammatory bowel diseases, inflammatory joint diseases and neurological diseases such as Multiple Sclerosis. The product candidates developed by TxCell consist of antigen-specific Type 1 regulatory cells (Ag-Tregs) generated ex-vivo from patient's peripheral blood in a proprietary manufacturing process (link). The company's lead product candidate, Ovasave, has completed a PI/II clinical trial in Crohn's disease patients, refractory to all current treatments.
Tmunity Therapeutics develops T Cell Receptor (TCR) engineered T cells, regulatory T cells (Treg), and universal engineered T cell platforms that exhibit control over T cell activation and direction in vivo. The company is also developing proprietary technologies to activate, expand, and genetically engineer T cells from peripheral blood, cord blood and tumors.
TRACT Therapeutics is developing a therapy dedicated to organ transplant success. The therapy involves the isolation and expansion of a patient's own naturally occurring T regulatory cells, known as Tregs.
Quell Therapeutics is a London-based biotech company developing immune cell therapies to target transplant rejection and autoimmune and inflammatory diseases.
Caladrius Biosciences is a clinical-stage development company with cell therapy products in development based on multiple technology platforms and targeting autoimmune and select cardiology indications. The company was founded in 2006 and is based in Basking Ridge, New Jersey.
Discover the right solution for your team
The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.